Hengrui Pharmaceutical (600276.SH) issued an announcement. The company and its subsidiary Shanghai Hengrui Pharmaceutical Co., Ltd. received the national drug...
Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. The company and its subsidiary Shanghai Hengrui Pharmaceutical Co., Ltd. have received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for darsilane sulfonate tablets and HRS8807 tablets, which will conduct clinical trials in the near future.